[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"angiokeratomas\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:angiokeratomas":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100635391",false,"NCT07552077","A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)","LOTU","Inclusion Criteria:\n\n* Participants must be 6 years or older\n* Diagnosed with angiokeratoma\n* Able and willing to comply with all protocol-related activities\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Any significant concurrent condition that could adversely affect participation\n* Any history of allergy or hypersensitivity to sirolimus, or sirolimus-like medications or to PTX-022\n* Patients deemed by the investigator as unwilling or unable to remain compliant with all tests and procedures, including adherence to study drug administration and other protocol-required activities","ALL","6 Years",{"count":18,"type":19},15,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","The purpose of this study is to evaluate the safety and effectiveness of the experimental drug PTX-022 in the treatment of angiokeratomas",[25],"Angiokeratomas",[27],"angiokeratoma","RECRUITING","2026-04-20",{"date":31,"type":32},"2026-04-27","ACTUAL",{"date":34,"type":19},"2026-04",{"date":36,"type":19},"2027-09",{"name":38,"class":39},"Palvella Therapeutics, Inc.","INDUSTRY",4,""]